Loading news...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report)'s share price passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.30 and traded as high as $5.00. Ironwood Pharmaceuticals shares last traded at $4.86, with a volume of 1,594,030 shares traded. Analyst Upgrades and Downgrades A
Stocks like IPGP, DG, IRWD and SAIC are seeing price strength and have a high chance of carrying the momentum forward.
The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works, sending the stock to the moon, or it fails, causing a crash.
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
IRWD shares jump on upbeat 2026 revenue guidance amid rising Linzess demand in the United States. The company also provides a key pipeline update.
U.S. stock futures rose in the first full trading week of the year on Monday after closing mixed on Friday. Futures of major benchmark indices were higher.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report)'s stock price hit a new 52-week high during trading on Friday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. The company traded as high as $5.78 and last traded at $5.24, with a volume of 39802325 shares changing hands. The stock
Ironwood Pharma (IRWD) is reaching a new 52-week high after reaffirming its FY25 guidance and releasing robust FY26 guidance. For FY25, IRWD anticipates total r
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming.
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
Ironwood Pharmaceuticals (NASDAQ: IRWD - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation. Insider and Institutional Ownership 16.9% of Citius
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) has been assigned a consensus rating of "Hold" from the eight analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating on the company.
Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.
Connor Clark and Lunn Investment Management Ltd. raised its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 48.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,206,948 shares of the biotechnology company's stock after buying an additional 718,904 shares during the
Acadian Asset Management LLC increased its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 147.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,549,687 shares of the biotechnology company's stock after acquiring an additional 3,904,498 shares during the quarter.
Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.
Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago.